TrialID,Countries,region_Africa,manual,study_arm,url,Scientific_title,Conditions,Date_enrollment_format,control_arm,randomisation,blinding,subject_blind,caregiver_blind,investigator_blind,outcome_blind,analyst_blind,prospective,Source_registry,phase_clean,region_N_America,region_L_America,region_Asia,region_Europe,region_Oceania,multicentre,primary_purpose,sponsor_type,sample_size,vaccine,conventional,traditional,Bridging_flag,Study_design,Day_inferred,Date_registration_format,Phase,Public_title,Primary_sponsor,Interventions
EUCTR2018-004056-37-GB,United States;Hong Kong;Greece;Spain;Costa Rica;Turkey;Israel;United Kingdom;Switzerland;India;Mexico;Argentina;Brazil;Singapore;South Africa;Japan;China,Yes,No,im,https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2018-004056-37,"A PHASE IIIB, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, CLINICAL EFFICACY STUDY OF BALOXAVIRMARBOXIL FOR THE REDUCTION OF DIRECT TRANSMISSION OF INFLUENZA FROM OTHERWISE HEALTHY PATIENTS TOHOUSEHOLD CONTACTS - Centerstone",Influenza <br>MedDRA version: 20.0Level: LLTClassification code 10022001Term: Influenza (epidemic)System Organ Class: 100000004862 <br>MedDRA version: 20.1Level: LLTClassification code 10022003Term: Influenza B virus infectionSystem Organ Class: 100000004862 <br>MedDRA version: 20.1Level: LLTClassification code 10022002Term: Influenza A virus infectionSystem Organ Class: 100000004862 <br>MedDRA version: 20.0Level: LLTClassification code 10016790Term: FluSystem Organ Class: 100000004862;Therapeutic area: Diseases [C] - Virus Diseases [C02],2019-09-11,Yes,Yes,Yes,NA,NA,NA,NA,NA,Yes,EUCTR,Phase 3,Yes,Yes,Yes,Yes,No,Yes,NA,industry,1130,NA,Yes,NA,NCT03969212,"Controlled: yesRandomised: yesOpen: noSingle blind: noDouble blind: yesParallel group: yesCross over: noOther: noIf controlled, specify comparator, Other Medicinial Product: noPlacebo: yesOther: noNumber of treatment arms in the trial: 2",FALSE,2019-07-24,Human pharmacology (Phase I): noTherapeutic exploratory (Phase II): noTherapeutic confirmatory - (Phase III): yesTherapeutic use (Phase IV): no,A Study of Baloxavir Marboxil for the Reduction of Direct Transmission of Influenza from Otherwise Healthy Patients to Household Contacts,F. Hoffmann-La Roche Ltd,<br>Product Name: Baloxavir marboxil<br>Product Code: RO7191686/F04<br>Pharmaceutical Form: Tablet<br>INN or Proposed INN: BALOXAVIR MARBOXIL<br>Current Sponsor code: RO7191686<br>Concentration unit: mg milligram(s)<br>Concentration type: equal<br>Concentration number: 20-<br>Pharmaceutical form of the placebo: Tablet<br>Route of administration of the placebo: Oral use<br><br>
NCT04454307,NA,Unreported,Yes,covid,https://clinicaltrials.gov/show/NCT04454307,Safety and Efficacy of Tramadol Adjuvant Therapy to Standard Care for COVID-19 Egyptian Patients: A Randomized Double Blind Controlled Clinical Trial,COVID-19,2020-07-01,Yes,Yes,Yes,Yes,Yes,No,No,No,Yes,CT.gov,Phase 2,Unreported,Unreported,Unreported,Unreported,Unreported,NA,Treatment,non_industry,100,NA,NA,NA,FALSE,"Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Double (Participant, Care Provider).",TRUE,2020-06-29,Phase 1/Phase 2,Safety and Efficacy of Tramadol in COVID-19 Egyptian Patients,Tanta University,Drug: Tramadol;Other: Standard care delivered in the isolation hospitals.
